IP Library Granted Patent US 12,263,232
Granted Patent B1
US 12,263,232 · App. 18/739,091 · Granted Apr 1, 2025

Composition for regulating production of proteins

Inventors: Jill L. Thompson (Calgary, CA); Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
A61K48/005A61K38/1774C12N15/86C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,232
App. No.
18/739,091
Granted
Apr 1, 2025
Kind
B1
Abstract

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject who is administered the one or more compositions. The target biomolecule is a precursor protein such as a precursor protein of CLTA4.

Claims (7)

1. A composition that comprises a recombinant plasmid (RP) comprising a sequence of-nucleotides that encodes a messenger ribonucleic acid (mRNA) that encodes a precursor protein, wherein the precursor protein is encoded by SEQ ID NO. 2.

2. The composition of claim 1 , wherein the sequence of nucleotides is inserted within a protein coat, a lipid vesicle, or any combination thereof.

3. The composition of claim 1 , wherein the sequence of nucleotides is inserted within in a viral vector.

4. The composition of claim 3 , wherein the viral vector is one of a double stranded DNA virus, a single stranded DNA virus, a single stranded RNA virus, or a double stranded RNA virus.

5. The composition of claim 3 , wherein the viral vector is an adeno-associated virus.

6. The composition of claim 1 , wherein the precursor protein is a precursor of Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4).

7. A composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides that encodes a sequence of messenger ribonucleic acid (mRNA) that encodes a precursor protein, wherein the sequence of nucleotides is SEQ ID NO. 3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2025
From: THOMPSON, JILL L.; THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072120/0345 →
References Cited (11)
US 11603541B2 · Thompson · 2023 [cited by examiner]
US 11873505B2 · Thompson · 2024 [cited by examiner]
US 20200368369A1 · Thompson · 2020 [cited by examiner]
US 20220251208A1 · Morsey · 2022 [cited by examiner]
US 20230340533A1 · Thompson · 2023 [cited by examiner]
Teng (et al. 2023. PAD2: A potential target for tumor therapy. BBA-Rev. Cancer 1878:188931) (Year: 2023). [cited by examiner]
Rouf (et al. 2023. The recent advances and future perspectives of genetic compensation studies in the zebrafish model. Genes & Diseases 10:468-479) (Year: 2023). [cited by examiner]
Wikipedia (2024. Post translational modification. Available online at: en.wikipedia.org/wiki/Post-translational_modification. Accessed on Sep. 10, 2024) (Year: 2024). [cited by examiner]
Wikipedia (2024. Expression vector. Available online at en.wikipedia.org. Accessed on Sep. 10, 2024) (Year: 2024). [cited by examiner]
American Society of Gene & Cell Therapy (2024. Vectors 101. Available online at asgct.org. Accessed on Sep. 11, 2024) (Year: 2024). [cited by examiner]
Wikipedia-Virus (2024. Group of pages: Flavivirus; Rotavirus; Dependoparvovirus; and Orthopoxvirus. Available online at en.wikipedia.org. Accessed on Sep. 10, 2024) (Year: 2024). [cited by examiner]